# Docetaxel Versus Cabazitaxel Post Abiraterone or Enzalutamide

> **NCT03764540** · PHASE2 · TERMINATED · sponsor: **Centre hospitalier de l'Université de Montréal (CHUM)** · enrollment: 57 (actual)

## Conditions studied

- Metastatic Prostate Cancer

## Interventions

- **DRUG:** Cabazitaxel plus prednisone
- **DRUG:** Docetaxel plus prednisone

## Key facts

- **NCT ID:** NCT03764540
- **Lead sponsor:** Centre hospitalier de l'Université de Montréal (CHUM)
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-04-01
- **Primary completion:** 2024-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 57 (ACTUAL)
- **Why stopped:** The cabazitaxel was recently approved by the regulatory authorities for mCRPCa
- **Last updated:** 2025-04-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03764540

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03764540, "Docetaxel Versus Cabazitaxel Post Abiraterone or Enzalutamide". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT03764540. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*